Odyssey is rapidly advancing programs in immunology and oncology, focusing on targets with strong validation that do not have marketed solutions. The current portfolio encompasses multiple programs that each address large market indications. While some of these programs can be addressed with conventional drug discovery paradigms, others employ more creative approaches and emerging technologies. To support growth of the pipeline, we are leveraging our expertise in immunology, cancer biology, translational medicine, and data science to discover new, high-potential targets that address unmet needs and advance the standard of care.
